Equities

4DMedical Ltd

4DMedical Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)0.685
  • Today's Change0.095 / 16.10%
  • Shares traded1.96m
  • 1 Year change-22.16%
  • Beta1.8192
Data delayed at least 20 minutes, as of Jun 07 2024 07:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

4DMedical Limited is an Australia-based medical technology company. Through its flagship patented XV Technology, the Company enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers its FDA-cleared XV Lung Ventilation Analysis Software (XV LVA), which is a modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS. XV LVAS and CT LVAS reports are prepared using the Company’s software as a service (SaaS) delivery model using existing hospital imaging equipment or the Company's XV Scanner. It initiated the commercial rollout of XV LVAS with I-MED Radiology Network (I-MED), which is a diagnostic imaging provider with approximately 250 clinics nationwide. The Company provides its lung imaging technology to other selected clinics across the I-MED network.

  • Revenue in AUD (TTM)1.03m
  • Net income in AUD-30.83m
  • Incorporated2012
  • Employees--
  • Location
    4DMedical LtdLevel 7 Melbourne Connect700 Swanston StreetMELBOURNE 3053AustraliaAUS
  • Phone+61 39545-5940
  • Websitehttps://4dmedical.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
4DX:ASX since
announced
Transaction
value
Imbio LLCDeal completed11 Dec 202311 Dec 2023Deal completed-27.89%69.30m
Data delayed at least 20 minutes, as of Jun 07 2024 07:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Genetic Signatures Ltd16.49m-18.04m136.16m----3.36--8.26-0.1245-0.12450.11360.21720.33661.065.25---36.81-7.14-40.19-7.8240.6657.68-109.38-13.745.95-18,040.000.0003---38.1133.44-558.77--73.20--
ImpediMed Ltd10.47m-19.42m149.71m76.00--2.94--14.29-0.0102-0.01020.00550.02520.19611.324.41137,802.60-36.37-52.27-40.94-62.3486.9580.64-185.47-264.766.85--0.0244--7.3627.87-3.26--37.83--
Mach7 Technologies Ltd26.97m-5.55m156.81m90.00--2.8872.455.81-0.0231-0.02310.11230.22560.3605--3.21---7.42-7.48-8.73-8.6595.0993.72-20.59-20.56---2,605.170.0193--10.9728.3074.85--29.28--
EMvision Medical Devices Ltd8.86m-3.22m159.74m----25.53--18.03-0.0449-0.04490.11860.07330.7954-------28.95-67.20-45.25-79.38-----36.40-175.99---35.200.3424--62.0870.4736.64------
Cyclopharm Limited32.21m-4.70m179.94m87.00--4.94--5.59-0.0508-0.05080.34760.34280.67481.114.13370,173.10-9.85-12.60-11.92-14.9468.1570.20-14.60-25.472.32-18.400.1159--11.2215.5028.90---7.83-12.94
Aroa Biosurgery Ltd64.20m-9.88m189.31m261.00--2.15--2.95-0.0287-0.02870.18670.25640.6071.562.82---9.34-10.37-10.11-12.5285.3980.63-15.39-20.316.40--0.0726--9.0124.26-2,583.84--33.65--
4DMedical Ltd1.03m-30.83m230.92m----2.53--225.24-0.0882-0.08820.00290.23320.00980.0920.1585---29.47-43.96-39.07-57.5895.0032.30-3,007.64-2,704.361.79--0.0476---31.84-1.86-27.92--2.46--
Paragon Care Ltd.317.39m10.31m253.79m0.0024.891.0111.500.79960.01530.01240.46980.37590.68063.008.84--2.54-1.783.32-2.3340.9239.553.73-2.580.71213.040.374--29.5521.27111.05-1.5426.29-17.29
EBR Systems Inc0.00-52.73m341.98m----7.29-----0.182-0.1820.000.15230.00-------46.54---50.70-------------28.660.5609-------5.89------
Data as of Jun 07 2024. Currency figures normalised to 4DMedical Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

4.57%Per cent of shares held by top holders
HolderShares% Held
Perennial Value Management Ltd.as of 22 Dec 202214.70m3.76%
Netwealth Investments Ltd.as of 16 Aug 20232.34m0.60%
BetaShares Capital Ltd.as of 30 Apr 2024592.40k0.15%
DFA Australia Ltd.as of 30 Apr 2024211.15k0.05%
Dimensional Fund Advisors LPas of 09 May 202454.14k0.01%
American Century Investment Management, Inc.as of 09 May 20242.41k0.00%
Norges Bank Investment Managementas of 31 Dec 20230.000.00%
More ▼
Data from 31 Jul 2021 - 06 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.